IP Library Granted Patent US 9,066,920
Granted Patent B2
US 9,066,920 · App. 13/380,305 · Granted Jun 30, 2015

Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,066,920
App. No.
13/380,305
Granted
Jun 30, 2015
Kind
B2
Abstract

This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.

Claims (13)

1. A method of treating partial seizure comprising administering cannabidiol (CBD), to a patient wherein the CBD is present in an amount which provides a daily dose of at least 400 mg.

2. The method of claim 1 , wherein CBD is present in an amount which provides a daily dose of from 400 to 800 mg.

3. The method of claim 1 , wherein the CBD is used in combination with tetrahydrocannabivarin (THCV).

4. The method of claim 3 , wherein the THCV is present in an amount which provides a daily dose of at least 1.5 mg.

5. The method of claim 4 , wherein the THCV is present in an amount which provides a daily dose of at least 15 mg.

6. The method of claim 1 , wherein the CBD is present as a plant extract.

7. The method of claim 6 , wherein the plant extract comprises less than 5% by weight of tetrahydrocannabinol (THC) as a percentage of any cannabinoids present in the plant extract.

8. The method of claim 7 , wherein the plant extract comprises less than 1% by weight of tetrahydrocannabinol (THC) as a percentage of any cannabinoids present in the plant extract.

9. The method of claim 1 , wherein the CBD is present as a pure or isolated cannabinoid.

10. The method of claim 3 , wherein the CBD in combination with THCV is present as a plant extract.

11. The method of claim 10 , wherein the plant extract comprises less than 5% by weight of tetrahydrocannabinol (THC) as a percentage of any cannabinoids present in the plant extract.

12. The method of claim 11 , wherein the plant extract comprises less than 1% by weight of tetrahydrocannabinol (THC) as a percentage of any cannabinoids present in the plant extract.

13. The method of claim 3 , wherein the CBD in combination with THCV is present as a pure or isolated cannabinoid.

Assignments (4)
CHANGE OF NAME Recorded May 13, 2025
From: GW PHARMA LIMITED
To: JAZZ PHARMACEUTICALS OPERATIONS UK LIMITED
Reel/Frame 071104/0142 →
SECURITY AGREEMENT Recorded Jul 22, 2021
From: GW PHARMA LIMITED; GW RESEARCH LIMITED
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 056958/0493 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2017
From: OTSUKA PHARMACEUTICAL CO., LIMITED
To: GW PHARMA LIMITED
Reel/Frame 044162/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2012
From: WHALLEY, BEN; STEPHENS, GARY; WILLIAMS, CLAIRE; GUY, GEOFFREY; WRIGHT, STEPHEN; KIKUCHI, TETSURO
To: GW PHARMA LIMITED; OTSUKA PHARMACEUTICAL CO. LIMITED
Reel/Frame 027879/0054 →